An interventional study of Dry Needling and Lidocaine Injection (1%, 2 mL) in Myofascial Pain Syndrome (Upper Trapezius), sponsored by Derince Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Derince Training and Research Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Myofascial Pain Syndromes with a site in Turkey — 12 open to participants now, 12 under way, none of them phase 3. Myofascial Pain Syndromes · Turkey.
Among the 81 studies in Myofascial Pain Syndromes with a site in Turkey, this one is the 12th largest by enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2025, is one of 62 with no phase, and was the 74th registered.
340 studies on the registry are indexed under Myofascial Pain Syndromes; 67 are open to participants now.
Browse Myofascial Pain Syndromes studies →12 of the 81 studies in Myofascial Pain Syndromes with a site in Turkey are open now. Recruiting first, the newest first:
ALİEMAN · Sites in Turkey
Ages 18–65
Istanbul University · Sites in Turkey
Ages 18–55
Ankara Etlik City Hospital · Sites in Turkey
Ages 18–65
Ankara University · Sites in Turkey
Ages 18–65
Gazi University · Sites in Turkey
Ages 18–35 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 35 Myofascial Pain Syndromes studies recruiting now, 6 (17%) set no upper age limit and 26 (74%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 51 across 308 interventional studies indexed under Myofascial Pain Syndromes.
Median enrollment 60 across the 67 interventional studies, 110 across the 14 observational. Of the 64 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 81 have an industry lead sponsor. The 10 most frequent:
Derince Training and Research Hospital is the lead sponsor of 39 studies on the registry; none are open to participants now.
Derince Training and Research Hospital has 1 study filed under Myofascial Pain Syndromes — fewer than ten, so there is no comparison to draw.
3 of the studies in Myofascial Pain Syndromes with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07926113Medipol UniversityComparison of 26G and 30G Needles for Masseter Trigger Point Injections in Patients With Myofascial Pain Syndrome | 2027-01 |
| NCT07511751ALİEMANCOMPARISON OF THREE TREATMENT MODALITIES IN MYOFASCIAL PAIN SYNDROME | 2027-03-10 |
| NCT07904364Mardin Artuklu UniversityAgreement Between CSI and IASP Pain Classification in Chronic Cervical Myofascial Pain | 2027-06-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 81 studies in Myofascial Pain Syndromes with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, assessor-blinded, three-arm randomized controlled trial comparing ultrasound-guided dry needling, lidocaine injection, and oxygen-ozone injection in patients with myofascial pain syndrome (MPS) of the upper trapezius muscle. A total of 81 participants were randomized (27 per arm) to receive the assigned intervention once weekly for 3 sessions plus a standardized home exercise program; 76 participants completed follow-up and were analyzed (dry needling, n=25; lidocaine, n=25; oxygen-ozone, n=26). Clinical (pain, function, sleep, quality of life) and ultrasonographic (tissue imaging, blood flow waveform) outcomes were assessed at baseline, Week 4, and Week 12.
Design: Prospective, three-arm, parallel-group randomized controlled trial with blinded outcome assessment and statistical analysis, conducted between June 2025 and August 2026.
Randomization: Computer-generated block randomization (1:1:1; block size = 6, with a final block of 3); allocation concealment with sequentially numbered, sealed, opaque envelopes. Of 110 patients screened, 81 were randomized (27 per group); 5 participants discontinued before completing the three treatment sessions, and 76 completed follow-up and were analyzed.
Blinding: Clinical and ultrasonographic outcomes were assessed by a separate physiatrist (10 years of experience in musculoskeletal ultrasonography) who was not involved in the interventions and was blinded to group allocation. Statistical analyses were performed on a coded dataset by an investigator blinded to group allocation. Blinding of participants and the interventionist was not feasible because of the nature of the interventions.
Interventions: All procedures were performed under real-time ultrasound guidance (GE LOGIQ P5, 4-15 MHz linear probe) and aseptic conditions by a single physiatrist and algologist with 15 years of experience in musculoskeletal ultrasonography, using a 40-mm, 27-gauge needle in all groups. In each patient, a single active trigger point (the most painful one, on the more symptomatic side) was treated unilaterally once weekly for three sessions. All participants performed a standardized daily home exercise program; analgesics, nonsteroidal anti-inflammatory drugs, and other treatments were not permitted during the study.
The criteria were revised on the registry on Nov 4, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ultrasound-guided dry needling of a single active upper trapezius trigger point using a 40-mm, 27-gauge needle with the fast-in, fast-out multidirectional technique to elicit local twitch responses, without injection of any substance. Once weekly for three sessions, combined with a standardized home exercise program.
Device: Dry Needling
Participants received ultrasound-guided injection of 2 mL of 1% lidocaine into a single active upper trapezius trigger point using a 40-mm, 27-gauge needle; local twitch responses were intentionally elicited with the same multidirectional technique as in the dry needling group, and the injectate was distributed in a fan-shaped manner within the trigger point. Once weekly for three sessions, combined with a standardized home exercise program.
Drug: Lidocaine Injection (1%, 2 mL)
Participants received ultrasound-guided injection of 5 mL of an oxygen-ozone mixture (ozone concentration 10 μg/mL) into a single active upper trapezius trigger point using a 40-mm, 27-gauge needle; local twitch responses were intentionally elicited with the same multidirectional technique as in the dry needling group, and the mixture was distributed in a fan-shaped manner within the trigger point. Once weekly for three sessions, combined with a standardized home exercise program.
Drug: Oxygen-Ozone Injection (10 μg/mL, 5 mL)
Ultrasound-guided dry needling of a single active upper trapezius trigger point using a 40-mm, 27-gauge needle with the fast-in, fast-out multidirectional technique (approximately 20 insertions over approximately 30 seconds) to elicit local twitch responses, continued until no further local twitch responses could be elicited. No substance was injected. Once weekly for three sessions, combined with a standardized home exercise program.
Ultrasound-guided injection of 2 mL of 1% lidocaine (1 mL of 2% lidocaine hydrochloride diluted with 1 mL of 0.9% sodium chloride immediately before injection) into a single active upper trapezius trigger point using a 40-mm, 27-gauge needle. Local twitch responses were intentionally elicited with the same multidirectional technique used in the dry needling group, and the injectate was distributed in a fan-shaped manner within the trigger point. Once weekly for three sessions, combined with a standardized home exercise program.
Ultrasound-guided injection of 5 mL of an oxygen-ozone mixture (ozone concentration 10 μg/mL, produced from medical-grade oxygen with a calibrated medical ozone generator and injected within 30 seconds of withdrawal) into a single active upper trapezius trigger point using a 40-mm, 27-gauge needle. Local twitch responses were intentionally elicited with the same multidirectional technique used in the dry needling group, and the mixture was distributed in a fan-shaped manner within the trigger point. Once weekly for three sessions, combined with a standardized home exercise program.
Pain Intensity (Visual Analog Scale, VAS)
"Pain intensity was assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain)."
Time frame: Baseline, Week 4, and Week 12
Neck Disability Index (NDI)
"Functional status was evaluated using the Neck Disability Index, a 10-item questionnaire with scores ranging from 0 to 50, where higher scores indicate greater disability."
Time frame: Baseline, Week 4, and Week 12
Pittsburgh Sleep Quality Index (PSQI)
Sleep quality assessed with the Pittsburgh Sleep Quality Index (PSQI). Global score range 0-21; higher scores indicate poorer sleep quality (scores \>5 indicate poor sleep).
Time frame: Baseline, Week 4, and Week 12
Short Form-36 (SF-36)
Health-related quality of life assessed with the Short Form-36 Health Survey (SF-36), reported for its eight domains (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health). Each domain is scored 0-100; higher scores indicate better health status.
Time frame: Baseline, Week 4, and Week 12
Tissue Imaging Score (TIS)
"Ultrasonographic tissue imaging score assessed via grayscale ultrasonography to evaluate echogenicity and structural characteristics of the trigger point muscle segment; scored 0 (normal homogeneous structure), 1 (single focal hypoechoic area), or 2 (multiple hypoechoic nodules)."
Time frame: Baseline, Week 4, and Week 12
Blood Flow Waveform Score (BFS)
Ordinal Doppler blood flow waveform score (BFS, 0-2) of the small intramuscular arterial branch closest to the trigger point site, based on pulsed-wave Doppler and the resistive index (RI = \[peak systolic velocity - end-diastolic velocity\] / peak systolic velocity): 0 = normal resting muscle arterial flow without diastolic flow (RI = 1); 1 = increased diastolic flow indicating reduced vascular bed resistance (RI \< 1); 2 = high-resistance waveform with retrograde (negative) diastolic flow (RI \> 1). Higher scores indicate a more abnormal waveform.
Time frame: Baseline, Week 4, and Week 12
Ran from Jun 2025 to primary completion in Aug 2026, 14 months.
Of 203 non-industry interventional studies with no phase under Myofascial Pain Syndromes, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 14 months is above that.
Counting every sponsor, half of 205 studies reached it within 5 months; a quarter within 2 and three quarters within 13.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion May 2026 → Aug 2026 and completion May 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Derince Training and Research Hospital